Investigation of the tolerability and potential health benefits of a novel butyrate generating supplement in a pilot human study
BACKGROUND: Butyrate is a health promoting short-chain fatty acid (SCFA) metabolite of fiber fermentation in the gut. Supplementing directly with a butyrate generator may be a dietary alternative with health benefits. OBJECTIVE: To evaluate the effect of tributyrin, a butyrate generator, on tolerabi...
Gespeichert in:
| Veröffentlicht in: | Nutrition and healthy aging 2024-10, Vol.9 (1), p.133-144 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 144 |
|---|---|
| container_issue | 1 |
| container_start_page | 133 |
| container_title | Nutrition and healthy aging |
| container_volume | 9 |
| creator | Smith, Morganne Lelah, Michael Goggans, Mallory Tunio, Sameer Naqib, Ankur Burton-Freeman, Britt Edirisinghe, Indika |
| description | BACKGROUND:
Butyrate is a health promoting short-chain fatty acid (SCFA) metabolite of fiber fermentation in the gut. Supplementing directly with a butyrate generator may be a dietary alternative with health benefits.
OBJECTIVE:
To evaluate the effect of tributyrin, a butyrate generator, on tolerability, gut microbiome composition, gut permeability, inflammation and metabolic markers in healthy adults at two dose levels.
METHODS:
Healthy adults (n = 29) were randomized to this single-blinded, two-arm, 28-day parallel design pilot study. Participants ingested one or two placebo capsules for 7 days followed by one or two (200 or 400 mg, respectively) ButyraGen® capsules, a novel tributyrin complex, daily for 21 days. Tolerability was assessed weekly by questionnaire. Blood and stool were collected at baseline and weekly for metabolic and inflammation markers, gut microbiome composition and SCFA concentrations, respectively. Urine was collected at baseline and end of the study for permeability assays.
RESULTS:
Twenty-four participants (n = 24, 25±8 years; 24.0±2.8 kg/m2; 66% male) completed the study. ButyraGen® was well-tolerated, with less than 10% (n = 2) reporting gastrointestinal-related discomfort. Fecal acetic (p = 0.03) and propionic (p = 0.03) acids decreased after supplementation (p = 0.03 and p = 0.03, respectively, n = 24) compared to baseline, and triglycerides increased (p = 0.02, 400 mg only, n = 11). Trends in decreased hs-CRP after 200 mg (p = 0.08) and 400 mg (p = 0.07) supplementation and decreased glucose (p = 0.10) after 200 mg supplementation was observed. No other changes in endpoints were observed.
CONCLUSIONS:
Tributyrin supplementation using ButyraGen® was safe and tolerable at the doses provided. Biological effects were observed suggesting butyrate generation and absorption in the small intestine followed by activity in the liver, though further investigation on mechanism of action is needed for confirmation. |
| doi_str_mv | 10.3233/NHA-240005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3110295888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.3233_NHA-240005</sage_id><sourcerecordid>3110295888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1315-2777c824eb6ef4e7a718f17a57ac1a85da3c001986e88f4cc0c6708720419c203</originalsourceid><addsrcrecordid>eNptkMFLwzAUxoMoOOYu_gUBD4JQTdJmSY9jqBOGXvRc0uy1zeiS2qSD3vzTzajixdP74P2-9_g-hK4puU9Zmj68blYJywgh_AzNWMZpknPCzn91JsklWni_jwQVnHPCZ-jrxR7BB1OrYJzFrsKhARxcC70qTWvCiJXd4c4FsMGoFjeg2tDgEixUJviTQ2HrjtDicghjrwLgOi6jMLbGfui6Fg7RjI2NZGdaF3AzHJTFPgy78QpdVKr1sPiZc_Tx9Pi-3iTbt-eX9WqbaJpSnjAhhJYsg3IJVQZCCSorKhQXSlMl-U6lOsbK5RKkrDKtiV4KIgUjGc01I-kc3Ux3u959DjFysXdDb-PLIqWUsJxLKSN1N1G6d973UBVdbw6qHwtKilPJRSy5mEqO8O0Ee1XD37l_yG_nMXwC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3110295888</pqid></control><display><type>article</type><title>Investigation of the tolerability and potential health benefits of a novel butyrate generating supplement in a pilot human study</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Smith, Morganne ; Lelah, Michael ; Goggans, Mallory ; Tunio, Sameer ; Naqib, Ankur ; Burton-Freeman, Britt ; Edirisinghe, Indika</creator><creatorcontrib>Smith, Morganne ; Lelah, Michael ; Goggans, Mallory ; Tunio, Sameer ; Naqib, Ankur ; Burton-Freeman, Britt ; Edirisinghe, Indika</creatorcontrib><description>BACKGROUND:
Butyrate is a health promoting short-chain fatty acid (SCFA) metabolite of fiber fermentation in the gut. Supplementing directly with a butyrate generator may be a dietary alternative with health benefits.
OBJECTIVE:
To evaluate the effect of tributyrin, a butyrate generator, on tolerability, gut microbiome composition, gut permeability, inflammation and metabolic markers in healthy adults at two dose levels.
METHODS:
Healthy adults (n = 29) were randomized to this single-blinded, two-arm, 28-day parallel design pilot study. Participants ingested one or two placebo capsules for 7 days followed by one or two (200 or 400 mg, respectively) ButyraGen® capsules, a novel tributyrin complex, daily for 21 days. Tolerability was assessed weekly by questionnaire. Blood and stool were collected at baseline and weekly for metabolic and inflammation markers, gut microbiome composition and SCFA concentrations, respectively. Urine was collected at baseline and end of the study for permeability assays.
RESULTS:
Twenty-four participants (n = 24, 25±8 years; 24.0±2.8 kg/m2; 66% male) completed the study. ButyraGen® was well-tolerated, with less than 10% (n = 2) reporting gastrointestinal-related discomfort. Fecal acetic (p = 0.03) and propionic (p = 0.03) acids decreased after supplementation (p = 0.03 and p = 0.03, respectively, n = 24) compared to baseline, and triglycerides increased (p = 0.02, 400 mg only, n = 11). Trends in decreased hs-CRP after 200 mg (p = 0.08) and 400 mg (p = 0.07) supplementation and decreased glucose (p = 0.10) after 200 mg supplementation was observed. No other changes in endpoints were observed.
CONCLUSIONS:
Tributyrin supplementation using ButyraGen® was safe and tolerable at the doses provided. Biological effects were observed suggesting butyrate generation and absorption in the small intestine followed by activity in the liver, though further investigation on mechanism of action is needed for confirmation.</description><identifier>ISSN: 2451-9480</identifier><identifier>EISSN: 2451-9502</identifier><identifier>DOI: 10.3233/NHA-240005</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adults ; Biological activity ; Biological effects ; Dietary supplements ; Digestive system ; Feces ; Fermentation ; Gastrointestinal tract ; Health promotion ; Inflammation ; Intestinal microflora ; Intestine ; Metabolism ; Metabolites ; Microbiomes ; Permeability ; Small intestine ; Triglycerides</subject><ispartof>Nutrition and healthy aging, 2024-10, Vol.9 (1), p.133-144</ispartof><rights>2024 – The authors. Published by IOS Press</rights><rights>Copyright IOS Press BV 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1315-2777c824eb6ef4e7a718f17a57ac1a85da3c001986e88f4cc0c6708720419c203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27905,27906</link.rule.ids></links><search><creatorcontrib>Smith, Morganne</creatorcontrib><creatorcontrib>Lelah, Michael</creatorcontrib><creatorcontrib>Goggans, Mallory</creatorcontrib><creatorcontrib>Tunio, Sameer</creatorcontrib><creatorcontrib>Naqib, Ankur</creatorcontrib><creatorcontrib>Burton-Freeman, Britt</creatorcontrib><creatorcontrib>Edirisinghe, Indika</creatorcontrib><title>Investigation of the tolerability and potential health benefits of a novel butyrate generating supplement in a pilot human study</title><title>Nutrition and healthy aging</title><description>BACKGROUND:
Butyrate is a health promoting short-chain fatty acid (SCFA) metabolite of fiber fermentation in the gut. Supplementing directly with a butyrate generator may be a dietary alternative with health benefits.
OBJECTIVE:
To evaluate the effect of tributyrin, a butyrate generator, on tolerability, gut microbiome composition, gut permeability, inflammation and metabolic markers in healthy adults at two dose levels.
METHODS:
Healthy adults (n = 29) were randomized to this single-blinded, two-arm, 28-day parallel design pilot study. Participants ingested one or two placebo capsules for 7 days followed by one or two (200 or 400 mg, respectively) ButyraGen® capsules, a novel tributyrin complex, daily for 21 days. Tolerability was assessed weekly by questionnaire. Blood and stool were collected at baseline and weekly for metabolic and inflammation markers, gut microbiome composition and SCFA concentrations, respectively. Urine was collected at baseline and end of the study for permeability assays.
RESULTS:
Twenty-four participants (n = 24, 25±8 years; 24.0±2.8 kg/m2; 66% male) completed the study. ButyraGen® was well-tolerated, with less than 10% (n = 2) reporting gastrointestinal-related discomfort. Fecal acetic (p = 0.03) and propionic (p = 0.03) acids decreased after supplementation (p = 0.03 and p = 0.03, respectively, n = 24) compared to baseline, and triglycerides increased (p = 0.02, 400 mg only, n = 11). Trends in decreased hs-CRP after 200 mg (p = 0.08) and 400 mg (p = 0.07) supplementation and decreased glucose (p = 0.10) after 200 mg supplementation was observed. No other changes in endpoints were observed.
CONCLUSIONS:
Tributyrin supplementation using ButyraGen® was safe and tolerable at the doses provided. Biological effects were observed suggesting butyrate generation and absorption in the small intestine followed by activity in the liver, though further investigation on mechanism of action is needed for confirmation.</description><subject>Adults</subject><subject>Biological activity</subject><subject>Biological effects</subject><subject>Dietary supplements</subject><subject>Digestive system</subject><subject>Feces</subject><subject>Fermentation</subject><subject>Gastrointestinal tract</subject><subject>Health promotion</subject><subject>Inflammation</subject><subject>Intestinal microflora</subject><subject>Intestine</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Microbiomes</subject><subject>Permeability</subject><subject>Small intestine</subject><subject>Triglycerides</subject><issn>2451-9480</issn><issn>2451-9502</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><recordid>eNptkMFLwzAUxoMoOOYu_gUBD4JQTdJmSY9jqBOGXvRc0uy1zeiS2qSD3vzTzajixdP74P2-9_g-hK4puU9Zmj68blYJywgh_AzNWMZpknPCzn91JsklWni_jwQVnHPCZ-jrxR7BB1OrYJzFrsKhARxcC70qTWvCiJXd4c4FsMGoFjeg2tDgEixUJviTQ2HrjtDicghjrwLgOi6jMLbGfui6Fg7RjI2NZGdaF3AzHJTFPgy78QpdVKr1sPiZc_Tx9Pi-3iTbt-eX9WqbaJpSnjAhhJYsg3IJVQZCCSorKhQXSlMl-U6lOsbK5RKkrDKtiV4KIgUjGc01I-kc3Ux3u959DjFysXdDb-PLIqWUsJxLKSN1N1G6d973UBVdbw6qHwtKilPJRSy5mEqO8O0Ee1XD37l_yG_nMXwC</recordid><startdate>20241018</startdate><enddate>20241018</enddate><creator>Smith, Morganne</creator><creator>Lelah, Michael</creator><creator>Goggans, Mallory</creator><creator>Tunio, Sameer</creator><creator>Naqib, Ankur</creator><creator>Burton-Freeman, Britt</creator><creator>Edirisinghe, Indika</creator><general>SAGE Publications</general><general>IOS Press BV</general><scope>AFRWT</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20241018</creationdate><title>Investigation of the tolerability and potential health benefits of a novel butyrate generating supplement in a pilot human study</title><author>Smith, Morganne ; Lelah, Michael ; Goggans, Mallory ; Tunio, Sameer ; Naqib, Ankur ; Burton-Freeman, Britt ; Edirisinghe, Indika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1315-2777c824eb6ef4e7a718f17a57ac1a85da3c001986e88f4cc0c6708720419c203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adults</topic><topic>Biological activity</topic><topic>Biological effects</topic><topic>Dietary supplements</topic><topic>Digestive system</topic><topic>Feces</topic><topic>Fermentation</topic><topic>Gastrointestinal tract</topic><topic>Health promotion</topic><topic>Inflammation</topic><topic>Intestinal microflora</topic><topic>Intestine</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Microbiomes</topic><topic>Permeability</topic><topic>Small intestine</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Morganne</creatorcontrib><creatorcontrib>Lelah, Michael</creatorcontrib><creatorcontrib>Goggans, Mallory</creatorcontrib><creatorcontrib>Tunio, Sameer</creatorcontrib><creatorcontrib>Naqib, Ankur</creatorcontrib><creatorcontrib>Burton-Freeman, Britt</creatorcontrib><creatorcontrib>Edirisinghe, Indika</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Nutrition and healthy aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Morganne</au><au>Lelah, Michael</au><au>Goggans, Mallory</au><au>Tunio, Sameer</au><au>Naqib, Ankur</au><au>Burton-Freeman, Britt</au><au>Edirisinghe, Indika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigation of the tolerability and potential health benefits of a novel butyrate generating supplement in a pilot human study</atitle><jtitle>Nutrition and healthy aging</jtitle><date>2024-10-18</date><risdate>2024</risdate><volume>9</volume><issue>1</issue><spage>133</spage><epage>144</epage><pages>133-144</pages><issn>2451-9480</issn><eissn>2451-9502</eissn><abstract>BACKGROUND:
Butyrate is a health promoting short-chain fatty acid (SCFA) metabolite of fiber fermentation in the gut. Supplementing directly with a butyrate generator may be a dietary alternative with health benefits.
OBJECTIVE:
To evaluate the effect of tributyrin, a butyrate generator, on tolerability, gut microbiome composition, gut permeability, inflammation and metabolic markers in healthy adults at two dose levels.
METHODS:
Healthy adults (n = 29) were randomized to this single-blinded, two-arm, 28-day parallel design pilot study. Participants ingested one or two placebo capsules for 7 days followed by one or two (200 or 400 mg, respectively) ButyraGen® capsules, a novel tributyrin complex, daily for 21 days. Tolerability was assessed weekly by questionnaire. Blood and stool were collected at baseline and weekly for metabolic and inflammation markers, gut microbiome composition and SCFA concentrations, respectively. Urine was collected at baseline and end of the study for permeability assays.
RESULTS:
Twenty-four participants (n = 24, 25±8 years; 24.0±2.8 kg/m2; 66% male) completed the study. ButyraGen® was well-tolerated, with less than 10% (n = 2) reporting gastrointestinal-related discomfort. Fecal acetic (p = 0.03) and propionic (p = 0.03) acids decreased after supplementation (p = 0.03 and p = 0.03, respectively, n = 24) compared to baseline, and triglycerides increased (p = 0.02, 400 mg only, n = 11). Trends in decreased hs-CRP after 200 mg (p = 0.08) and 400 mg (p = 0.07) supplementation and decreased glucose (p = 0.10) after 200 mg supplementation was observed. No other changes in endpoints were observed.
CONCLUSIONS:
Tributyrin supplementation using ButyraGen® was safe and tolerable at the doses provided. Biological effects were observed suggesting butyrate generation and absorption in the small intestine followed by activity in the liver, though further investigation on mechanism of action is needed for confirmation.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.3233/NHA-240005</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2451-9480 |
| ispartof | Nutrition and healthy aging, 2024-10, Vol.9 (1), p.133-144 |
| issn | 2451-9480 2451-9502 |
| language | eng |
| recordid | cdi_proquest_journals_3110295888 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adults Biological activity Biological effects Dietary supplements Digestive system Feces Fermentation Gastrointestinal tract Health promotion Inflammation Intestinal microflora Intestine Metabolism Metabolites Microbiomes Permeability Small intestine Triglycerides |
| title | Investigation of the tolerability and potential health benefits of a novel butyrate generating supplement in a pilot human study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T05%3A01%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigation%20of%20the%20tolerability%20and%20potential%20health%20benefits%20of%20a%20novel%20butyrate%20generating%20supplement%20in%20a%20pilot%20human%20study&rft.jtitle=Nutrition%20and%20healthy%20aging&rft.au=Smith,%20Morganne&rft.date=2024-10-18&rft.volume=9&rft.issue=1&rft.spage=133&rft.epage=144&rft.pages=133-144&rft.issn=2451-9480&rft.eissn=2451-9502&rft_id=info:doi/10.3233/NHA-240005&rft_dat=%3Cproquest_cross%3E3110295888%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3110295888&rft_id=info:pmid/&rft_sage_id=10.3233_NHA-240005&rfr_iscdi=true |